Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration

Purpose: Clinical trials have demonstrated that switching patients from intravitreal bevacizumab (IVB) or ranibizumab (IVR) to aflibercept (IVA) for treatment-refractory neovascular age-related macular degeneration (nAMD) can decrease the injection frequency. This study evaluated whether there was a...

Full description

Bibliographic Details
Main Authors: Simon D Archambault, Megan M Nichols, James C McCullum, Yubo Zhang, Elise E Steinberger, David J Ramsey
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-01-01
Series:Indian Journal of Ophthalmology
Subjects:
aflibercept
bevacizumab
medication adherence
neovascular age-related macular degeneration
patient compliance
ranibizumab
visual acuity
Online Access:http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=13;spage=101;epage=1015;aulast=Archambault

Internet

http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=13;spage=101;epage=1015;aulast=Archambault

Similar Items